- In late January 2026, Lightmatter announced a collaboration with Synopsys to integrate Synopsys’ 224G SerDes and UCIe IP for 3nm processes into its Passage 3D Co-Packaged Optics platform, aiming to improve bandwidth, latency and energy efficiency for advanced AI infrastructure.
- This pairing of Synopsys’ silicon-proven IP and AI-powered design tools with Lightmatter’s photonic architecture highlights how chip design and optics are converging to accelerate high-performance AI systems.
- Next, we’ll explore how this AI-focused collaboration and its emphasis on energy-efficient, high-bandwidth connectivity could influence Synopsys’ broader investment narrative.
The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
What Is Synopsys' Investment Narrative?
For Synopsys, you really have to believe that custom silicon and AI workloads keep pushing chipmakers toward tighter integration of compute, memory and optics, and that Synopsys’ tools and IP remain central to that shift. The Lightmatter collaboration fits neatly into this story, but it is unlikely to change the near term picture on its own, given Synopsys’ US$7,054.18 million revenue base and diversified customer set. The more immediate talking points still look like a rich valuation multiple, modest forecast growth, and a one off gain that flatters recent earnings quality, all against a share price that has lagged the wider market over the past year. The new co packaged optics angle slightly strengthens the AI connectivity and energy efficiency narrative, but it does not erase questions around pricing, return on equity and CEO pay.
However, one issue around profitability and management incentives is something investors should not ignore. Synopsys' share price has been on the slide but might be up to 27% below fair value. Find out if it's a bargain.Exploring Other Perspectives
Explore 6 other fair value estimates on Synopsys - why the stock might be worth 21% less than the current price!
Build Your Own Synopsys Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Synopsys research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
- Our free Synopsys research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synopsys' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it. Find the list for free.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com